Francesco Sclafani, Clare Peckitt, David Cunningham, Diana Tait, Jordi Giralt, Bengt Glimelius, Susana Roselló Keränen, Andrew Bateman, Tamas Hickish, Josep Tabernero, Janet Thomas, Gina Brown, Jacqueline Oates, Ian Chau
OBJECTIVE: Intensified preoperative treatments have been increasingly investigated in locally advanced rectal cancer (LARC), but limited data are available for the impact of these regimens on quality of life (QoL) and bowel function (BF). We assessed these outcome measures in EXPERT-C, a randomized phase 2 trial of neoadjuvant capecitabine combined with oxaliplatin (CAPOX), followed by chemoradiation therapy (CRT), total mesorectal excision, and adjuvant CAPOX with or without cetuximab in magnetic resonance imaging-defined, high-risk LARC...
October 1, 2015: International Journal of Radiation Oncology, Biology, Physics